FLORHAM PARK, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences:
To access the live webcast and archived recordings of the fireside chats, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recordings will be available for 90 days following each event.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
This email address is being protected from spambots. You need JavaScript enabled to view it.
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
This email address is being protected from spambots. You need JavaScript enabled to view it.
© 2023 Phathom Pharmaceuticals. All rights reserved.
Last Trade: | US$10.50 |
Daily Change: | 0.20 1.94 |
Daily Volume: | 466,343 |
Market Cap: | US$614.670M |
May 15, 2024 May 09, 2024 March 07, 2024 January 31, 2024 |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB